Rallybio RLYB
NASDAQ RLYB
$16.78 -0.42 (-2.45%)
As of: Oct 1, 2026 · 3:50 PM EDT

Rallybio (RLYB) Current Deferred Revenue (2024 - 2025)

Updated

Rallybio's Current Deferred Revenue came in at $212,000 for Q4 2025, down 75.0% from $848,000 a year earlier and down 50.0% from the prior quarter.

Analysis

Rallybio (RLYB) Current Deferred Revenue (2024 - 2025) Analysis & Trends

Going back to Q2 2024, Rallybio's Current Deferred Revenue data covers 7 quarters.

  • Going back by year, Current Deferred Revenue was $848,000 in FY2024.
  • Year-over-year, Current Deferred Revenue has declined for three consecutive quarters.
  • Business Quant data shows RLYB's Current Deferred Revenue at $424,000 (Q3 2025), $636,000 (Q2 2025) and $848,000 (Q1 2025) in the three quarters before Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Rallybio 91.28 Mn 91.28 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 212,000.00
Sep 30, 2025 424,000.00
Jun 30, 2025 636,000.00
Mar 31, 2025 848,000.00
Dec 31, 2024 848,000.00
Sep 30, 2024 1.10 Mn
Jun 30, 2024 1.20 Mn
API Access

Rallybio Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=RLYB&period=max&api_key=YOUR_API_KEY